257 related articles for article (PubMed ID: 15764267)
1. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
5. Urinary NMP22 and renal cell carcinoma.
Huang S; Rhee E; Patel H; Park E; Kaswick J
Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
[TBL] [Abstract][Full Text] [Related]
6. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
9. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
10. [The study of relationship between nuclear metrix protein 22 urinary level and the grade and stage of bladder transitional cell carcinoma].
Xin DQ; You R; Ding Y; Liu LQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2006 May; 44(10):681-3. PubMed ID: 16784679
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
12. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
Carpinito GA; Stadler WM; Briggman JV; Chodak GW; Church PA; Lamm DL; Lange PH; Messing EM; Pasciak RM; Reservitz GB; Ross RN; Rukstalis DB; Sarosdy MF; Soloway MS; Thiel RP; Vogelzang N; Hayden CL
J Urol; 1996 Oct; 156(4):1280-5. PubMed ID: 8808854
[TBL] [Abstract][Full Text] [Related]
13. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
Miyoshi Y; Matsuzaki J; Miura T
Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
16. [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
Chen HQ; Han CZ; Du LL; Cui Y; Pang DZ; Jing JX; Zhao XW; Tian BG; Mi ZG
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():84-6. PubMed ID: 17767866
[TBL] [Abstract][Full Text] [Related]
17. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
19. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
20. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
